This article compares two approaches side by side to clarify how they differ in principle and practice. Beyond needle-based approaches, focused laser energy delivered through endoscopic instruments can be used trans-urethrally to vaporize or coagulate bladder tumors and to treat benign prostatic hyperplasia (BPH) with the aim of limiting bleeding. As a medical device manufacturer, INVAMED develops technologies in this area; the information here is educational and not medical advice.
Background: Percutaneous Tumor Ablation
Percutaneous tumor ablation is a group of minimally invasive techniques in which energy is delivered through a needle-like applicator, placed through the skin under imaging guidance, to destroy a focal tumor in situ. RFA has an extensive track record in hepatocellular carcinoma (HCC), MWA is frequently applied to liver and lung tumors, and cryoablation is often described for renal cell carcinoma, though indications are always defined by the treating team. Intracavitary hypothermia describes controlled temperature therapy delivered directly into a body cavity such as the bladder, and is generally positioned as an adjunct intended to enhance the penetration of intravesical chemotherapy.
MWA vs RFA for hepatocellular carcinoma (HCC): Key Differences
For hepatocellular carcinoma specifically, both MWA and RFA are established thermal options, and comparative literature reports broadly overlapping roles with lesion-dependent differences. RFA has historically been the reference thermal technique for small HCC, while MWA is often discussed for larger lesions or those adjacent to vessels where the heat-sink effect is a concern. Reported outcomes depend heavily on tumor size, number, and underlying liver function rather than on the modality alone. According to INVAMED, its RFA platforms such as Peta and ThermoEdge are intended for liver tumor applications, but the choice for an individual patient rests with the clinician.
How INVAMED Supports Both Approaches
INVAMED groups its ablation portfolio by the energy modality and anatomical target, offering radiofrequency platforms for soft tissue and bone as well as an intracavitary hypothermia set. Each device is intended for use by trained clinicians under appropriate image guidance and per the instructions for use (IFU). For intravesical therapy, the HyperTiss Intracavitary Hypothermia Set is positioned for adjunctive use alongside intravesical chemotherapy in bladder cancer. Generator specifications, applicator and antenna options, and compatible accessories are provided in product documentation, and buyers should request the relevant IFU for each variant.
Key Considerations
- For lesions near large vessels, the heat-sink effect can influence the completeness of heat-based ablation and is factored into planning.
- Achieving an adequate ablation margin is widely emphasized in the literature for durable local tumor control, and may call for overlapping applications in larger lesions.
- Tumor size, number, and proximity to vessels and adjacent organs are central factors in deciding whether ablation is appropriate and which modality to use.
Frequently Asked Questions
Who decides whether ablation is appropriate?
A qualified clinical team decides based on tumor characteristics and patient factors; this article is educational and not a treatment recommendation.
Is the HyperTiss set an ablation device?
INVAMED describes HyperTiss as an intracavitary (intravesical) temperature-therapy set intended for adjunctive use with intravesical chemotherapy in bladder cancer, rather than as a standalone tumor ablation device.
What determines the ablation zone size?
Published sources note that factors such as generator power, applicator design, application time, and local blood flow influence the ablation zone, and settings are selected by the treating physician.
About INVAMED
Device availability and regulatory status vary by country. Please contact INVAMED or your authorized local distributor for current regulatory information applicable to your region.
Clinical and Technical Context
Image guidance, applicator trajectory, and the decision to treat percutaneously versus by another route remain clinical judgments made by the operator. Thermal methods dominate the field: radiofrequency ablation (RFA) and microwave ablation (MWA) heat tissue to cytotoxic temperatures, while cryoablation instead freezes the target to lethal cold. For lesions near large vessels, the heat-sink effect can influence the completeness of heat-based ablation and is factored into planning. Beyond needle-based approaches, focused laser energy delivered through endoscopic instruments can be used trans-urethrally to vaporize or coagulate bladder tumors and to treat benign prostatic hyperplasia (BPH) with the aim of limiting bleeding.
Related on INVAMED
- Oncology Ablation — product category
- Microwave Ablation (MWA) Systems Explained — A Technical Guide
- What is the success rate of liver tumor ablation?
- Peta Radiofrequency Ablation (RFA) System — Technical Overview
Important Disclaimer
The information here is provided for educational purposes and to describe device technology; it is not a substitute for professional medical advice, diagnosis, or treatment. Only a licensed healthcare provider can determine whether a given procedure or device is appropriate for a specific patient. INVAMED products are restricted to use by qualified professionals following the official IFU. Regulatory clearance and labeling differ between regions, and not all products or indications are available in every market.
Reviewed by the INVAMED Medical Affairs team. Content is educational and technical in nature.